Creator: Help Dementia Editorial Team
Published: 2026-04-02T21:30:45

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

New dementia sits at the center of this dementia and brain health question.

The reason most primary care doctors don’t mention the new dementia blood tests during your annual physical comes down to four interconnected factors: they’re simply unaware the tests exist, the tests are brand new to the market, these tests aren’t designed for routine screening, and the financial and logistical barriers are significant. Research shows that fewer than 15% of primary care physicians are aware of or currently use Alzheimer’s blood biomarker tests—a stark contrast to the over 65% who are familiar with standard cognitive assessments.

If your doctor didn’t mention the test at your last checkup, this wasn’t an oversight or negligence; it reflects a broader gap between what’s available in the medical system and what’s filtered down to primary care offices. This article explores why these important new diagnostic tools remain largely invisible during routine doctor visits, even as they’re being hailed as breakthrough developments in dementia detection. Understanding these barriers also helps you know whether asking for the test makes sense at your next appointment, and what to expect if you do.

Why Are Primary Care Doctors Unaware of These New Blood Tests?
The Timeline Problem—These Tests Are Remarkably New to Medicine
These Blood Tests Aren’t Meant for Routine Screening—Only for Symptomatic Patients
The Cost and Insurance Coverage Barriers Create Real Obstacles
Lack of Clear Clinical Guidelines and Education Creates Uncertainty
What Primary Care Doctors Are Using Instead
What’s Changing—Wider Access and Growing Awareness
Conclusion

Why Are Primary Care Doctors Unaware of These New Blood Tests?

The adoption rate for Alzheimer’s blood biomarker tests among primary care physicians sits at less than 15%—a figure that becomes even more striking when you consider that awareness of standard cognitive assessments exceeds 65% and knowledge of other non-Alzheimer’s blood tests surpasses that same threshold. This awareness gap exists for several reasons. Primary care doctors are inundated with new medical developments each year, and specialty tests—particularly those related to emerging biomarkers—often take years to filter down from neurology journals into routine practice. Marketing for these blood tests, unlike some other medical tests, hasn’t aggressively targeted primary care offices.

Most information is still confined to academic centers and memory clinics where neurologists and geriatricians work. The gap becomes even more pronounced when you consider the competing demands on a primary care doctor’s time. A typical family medicine or internal medicine practice deals with diabetes management, hypertension, cancer screening, vaccinations, and dozens of other health priorities. A test that’s only one year or two years old, that requires new workflows, that has unclear insurance reimbursement, and that patients themselves aren’t asking for simply doesn’t rise to the top of the priority list. This isn’t a failure of individual doctors; it’s a systemic issue in how new medical information spreads through primary care.

Why Are Primary Care Doctors Unaware of These New Blood Tests?

The Timeline Problem—These Tests Are Remarkably New to Medicine

The Lumipulse blood test received FDA approval in May 2025—less than a year before many primary care offices began seeing annual physicals. The Elecsys pTau181 test followed in October 2025. Labcorp, one of the largest lab networks in the United States, only launched the first FDA-cleared version designed specifically for primary care settings in February 2026. If we’re currently in April 2026, this means the primary care-friendly version has been available for just two months.

Consider the timeline for adoption: a doctor has to learn that the test exists, understand what it measures, figure out which patients might benefit, navigate insurance requirements, train their staff on how to order it, and integrate it into workflows. All of this typically takes 12 to 24 months for new tests. Your doctor may have trained 15 or 20 years ago, and their last major continuing medical education update on dementia diagnostics might reference PET scans or cognitive testing—tools that have been standard for decades. The blood tests represent a fundamental shift in how dementia can be detected, but this shift is so recent that it hasn’t yet made it into most medical school curricula or standard primary care training programs. This explains why even conscientious doctors might not mention something they simply haven’t yet integrated into their practice or understanding of dementia care.

These Blood Tests Aren’t Meant for Routine Screening—Only for Symptomatic Patients

A critical misunderstanding drives much of the frustration around these tests: they aren’t designed to be used during a routine annual physical on asymptomatic people. The blood tests identify Alzheimer’s disease biomarkers in patients who are already experiencing cognitive symptoms—memory loss, difficulty with language, confusion, or other signs of cognitive decline. They’re diagnostic tools for people with a suspected problem, not screening tools for healthy people. If you’re feeling fine cognitively, showing no signs of memory loss, and functioning normally in your daily life, the test isn’t indicated for you regardless of your age.

This distinction explains a lot about why doctors don’t mention the test during annual physicals. The visit is designed to screen for common, preventable conditions—high cholesterol, high blood pressure, cancer, infections. It’s not the setting where you assess for symptomatic disease. If a doctor suspects cognitive decline based on your conversation and responses, or if you report memory problems yourself, that’s when the test becomes relevant. The test requires a specific clinical scenario—symptoms of possible cognitive impairment—that simply doesn’t apply to most people coming in for a routine checkup.

These Blood Tests Aren't Meant for Routine Screening—Only for Symptomatic Patients

The Cost and Insurance Coverage Barriers Create Real Obstacles

These blood tests are expensive. While exact pricing varies by lab and test, they typically cost several hundred dollars per test. More importantly, insurance coverage remains inconsistent and often limited. Many private insurers, along with Medicare and Medicaid, haven’t yet established clear reimbursement policies for these newly approved tests.

This creates a practical problem for primary care doctors: a patient might ask for the test, but unless the doctor can be reasonably confident that insurance will cover it, they’re essentially asking the patient to pay out-of-pocket for a diagnostic test—a difficult conversation for any physician. The financial barrier cuts both directions. For healthcare systems and clinics that operate on tight margins, adding a new test requires purchasing equipment, training staff, and managing billing—investments that many small primary care offices simply can’t justify for a test that they’ll use infrequently. A large hospital system or integrated health network like Mayo Clinic might integrate the test quickly; a solo practitioner or small clinic might not. This creates a two-tier system where access to the test depends partly on where you receive care, not just whether the test itself exists.

Lack of Clear Clinical Guidelines and Education Creates Uncertainty

Doctors are trained to practice according to evidence-based guidelines. When the American Academy of Neurology, the American Association for Geriatric Psychiatry, or other major medical organizations release guidelines, these heavily influence clinical practice. For the new blood tests, comprehensive guidelines for primary care use are still being developed. The American Academy of Neurology has published some guidance, but it’s new and still being integrated into practice.

Primary care physicians often wait for clear guidelines before adopting a new test, and those guidelines don’t yet exist in a form that definitively tells them how and when to order these tests in routine practice. Additionally, doctors express a clear willingness to adopt these tests—but only if they receive the right support. Research specifically shows that primary care physicians indicate they would use these tests “provided that they receive enhanced education, clear guidelines, and reimbursement support.” In other words, most doctors aren’t rejecting the tests based on skepticism; they’re waiting for the infrastructure to support using them. Education materials, training programs, and clear guidance about appropriate use cases are still being developed. Until those resources exist at scale, the tests will remain primarily in the hands of specialists.

Lack of Clear Clinical Guidelines and Education Creates Uncertainty

What Primary Care Doctors Are Using Instead

During annual physicals, doctors typically assess cognitive health through conversation and observation. If you seem confused, repeat questions, or show signs of cognitive difficulties, a primary care doctor might order cognitive screening tests like the Montreal Cognitive Assessment (MoCA) or Mini-Cog—tools that have been standard for years and are well-integrated into primary care. If screening results suggest cognitive problems, the doctor might then refer you to a neurologist or memory clinic, where specialists have more resources to order advanced tests, including the new blood tests.

This referral pathway actually makes sense clinically. A neurologist or geriatrician seeing a patient with actual cognitive symptoms is in a better position to assess whether the blood test is appropriate, order it, and interpret the results in the context of a full neurological evaluation. The primary care doctor’s role is often to identify that something might be wrong and refer appropriately, rather than to order the most advanced tests themselves. This division of labor is standard in medicine, even if it means that breakthrough tests take longer to filter down to routine primary care practice.

What’s Changing—Wider Access and Growing Awareness

The February 2026 launch of Labcorp’s FDA-cleared blood test specifically designed for primary care settings represents a turning point. As the major lab networks make these tests easier to order through standard lab request systems, adoption in primary care will likely accelerate significantly over the next 12 to 24 months. Additionally, more professional organizations are developing educational materials and practice guidelines specifically for primary care physicians.

Looking forward, expect to see these tests mentioned more frequently in routine doctor’s visits, particularly as doctors receive ongoing education and as insurance coverage becomes more standardized. The lag between FDA approval and routine clinical use—which we’re seeing right now with these blood tests—is normal and doesn’t reflect a failure of medicine. It reflects the time it takes for new tools to be understood, integrated into workflows, and widely taught. Within a couple of years, the story of why primary care doctors didn’t mention the blood test may seem quaint compared to a future where they routinely offer it to appropriate patients.

Conclusion

The reason your doctor likely didn’t mention the new Alzheimer’s blood tests during your annual physical isn’t because they don’t care about early detection or your cognitive health. It’s because these tests are remarkably new (approved in 2025-2026), awareness among primary care physicians remains very low (below 15%), the tests aren’t designed for routine screening in asymptomatic people, and the practical barriers—cost, insurance coverage, lack of clear guidelines—are still being worked out. The medical system is moving faster than it appears, with major changes already underway.

If you’re concerned about cognitive changes, the next step is to bring it up directly with your doctor. Tell them specifically what you’ve noticed—memory problems, difficulty following conversations, trouble with familiar tasks—rather than asking for the test by name. If your doctor doesn’t have access to the blood test immediately, they can refer you to a neurologist or memory clinic where specialists are already using these new tools. The test exists and is becoming more available every month; knowing when to ask for it makes all the difference.